-

$undefined

N/A

(N/A)

Sutro Biopharma NASDAQ:STRO Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Using precise protein engineering and rational design, Sutro is advancing next-generation oncology therapeutics.

Location: 310 Utah Ave Ste 150, California, 94080-6803, US | Website: www.sutrobio.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-110.1M

Cash

426M

Avg Qtr Burn

-18.68M

Short % of Float

4.64%

Insider Ownership

0.96%

Institutional Own.

78.18%

Qtr Updated

06/30/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Luveltamab Tazevibulin (luvelta) (FolRα-Targeting ADC) Details Cancer, Platinum-resistant ovarian cancer	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Luveltamab Tazevibulin (luvelta) (FolRα-Targeting ADC) Details Cancer, Acute myeloid leukemia	Phase 2/3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Luveltamab Tazevibulin (luvelta) (FolRα-Targeting ADC) Details Cancer, Non-small cell lung carcinoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Luveltamab Tazevibulin (luvelta) (FolRα-Targeting ADC) + bevacizumab Details Ovarian cancer, Cancer, Endometrial cancer	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
STRO-001 (BN301) (CD74-Targeting ADC) Details Follicular lymphoma, Mantle cell lymphoma, Lymphoma, B-cell lymphoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
M1231 (MUC1-EGFR Bispecific ADC) Details Solid tumor/s, Esophageal cancer, Non-small cell lung carcinoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.